Published in Immunotherapy Weekly, April 6th, 2005
"Activation of the KIT receptor tyrosine kinase contributes to the pathogenesis of several human diseases, but the mechanisms regulating KIT signaling have not been fully characterized.
"Here, we show that stem cell factor (SCF), the ligand for KIT, induces the interaction between KIT and Cbl proteins and their mutual degradation," wrote scientists from the United States.
"Upon SCF stimulation," wrote S. Zeng and coworkers at Columbia University, "KIT binds to and induces the phosphorylation of Cbl proteins, which in turn act as E3 ligases, mediating the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
Source: Immunotherapy Weekly (2005-04-06)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.